GLP-1 Receptor Agonists and Risk of Suicide or Suicide Attempts – A Nationwide Cohort and Self-Controlled Case Series Study

Why It Matters

The results reassure clinicians, patients, and regulators that GLP‑1 RAs, now widely used for diabetes and obesity, are not linked to higher suicide risk, supporting continued prescribing and ongoing pharmacovigilance.

Key Takeaways

• Study included over 200,000 GLP‑1 RA new users nationwide
• Adjusted hazard ratio vs DPP‑4 inhibitors was 0.58 (95% CI 0.37‑0.91)
• No increased suicide risk observed compared with SGLT‑2 inhibitors (HR 0.93)
• Self‑controlled case series showed lower incidence rates during treatment periods

Pulse Analysis

Regulatory agencies have faced mounting pressure to clarify the safety profile of GLP‑1 receptor agonists after dozens of spontaneous reports of suicidal ideation surfaced in Europe and the United States. While the drugs are celebrated for their glycaemic control, cardiovascular benefits, and recent approval for obesity treatment, the specter of mental‑health side effects has lingered, prompting formal investigations by the EMA and FDA. This Danish cohort leverages the country's comprehensive health registers, linking prescription data with mortality and hospital records, to provide a population‑scale assessment that overcomes many limitations of earlier case‑control studies and small‑sample RCT meta‑analyses.

The analysis compared GLP‑1 RA initiators with patients starting SGLT‑2 or DPP‑4 inhibitors—drugs used at similar disease stages but without known psychiatric signals. After adjusting for age, sex, education, and a broad range of somatic and psychiatric comorbidities, the hazard ratio for suicide or attempts was 0.93 versus SGLT‑2 inhibitors and 0.58 versus DPP‑4 inhibitors, indicating no excess risk and even a potential protective effect in the latter comparison. Sensitivity checks showed consistent findings across subgroups, including those with recent psychiatric histories, and the self‑controlled case series confirmed lower incidence rate ratios during treatment periods, suggesting that increased clinical contact rather than a drug‑specific mechanism may drive the observed safety.

These results carry practical implications for clinicians managing type‑2 diabetes and obesity. The data suggest that concerns about suicidal behavior should not deter the prescription of GLP‑1 RAs, especially given their proven metabolic and cardiovascular advantages. Nonetheless, the study underscores the importance of ongoing pharmacovigilance and individualized patient monitoring, particularly for individuals with pre‑existing mental‑health conditions. As the therapeutic landscape evolves, robust real‑world evidence such as this will remain essential for balancing efficacy with safety in chronic disease management.